Sickle Cell Vaso-Occlusive Crisis: Evaluation and Treatment
Micro-brief created with inScope · Clinically reviewed by Yasmine Abbey, MD, MSc · Last reviewed:
Educational summary for clinicians. Not medical advice — verify against primary sources, your clinical judgment, and institutional protocols.
Bottom line
Treat a vaso-occlusive crisis as an emergency: give a rapid-acting IV opioid (morphine or hydromorphone) within 60 minutes of arrival, reassess every 30–60 minutes, and repeat until pain is controlled. Add a short 5–7 day NSAID course unless contraindicated (ASH suggests, for example, ketoprofen 300 mg/day IV then 100 mg PO every 8 hours).
In parallel, give isotonic IV fluids without over-hydrating, supplemental oxygen if SpO2 is < 94% with incentive spirometry to reduce acute chest syndrome risk, and actively screen for complications — acute chest syndrome, infection, and stroke.
Initial workup
- Focused exam: pain location and severity, fever, and respiratory status; look for acute chest syndrome (ACS) or neurologic deficits.
- Baseline labs: CBC with differential and reticulocytes, BMP, liver panel, type and screen, LDH, and bilirubin to assess hemolysis and transfusion need.
- Infection and complication screen: blood ± urine cultures and a chest radiograph if febrile, hypoxic, or with chest pain or cough, to rule out ACS or pneumonia.
- Pulse oximetry ± arterial blood gas if SpO2 is < 94%; consider CT or ultrasound for limb swelling (DVT) or abdominal pain (splenic or hepatic sequestration).
Acute management
- Analgesia within 60 minutes of presentation: a rapid-acting IV opioid (e.g., morphine or hydromorphone), reassessed every 30–60 minutes and repeated until adequate pain control.
- Adjunctive NSAID: a short 5–7 day course unless contraindicated; ASH suggests agents such as ketoprofen 300 mg/day IV then 100 mg PO every 8 hours as tolerated.
- Hydration: isotonic IV fluids (avoid over-hydration) with encouragement of oral intake; correct electrolyte abnormalities.
- Supplemental oxygen if SpO2 is < 94%, with incentive spirometry to reduce ACS risk.
- Evaluate and treat triggers: empiric antibiotics for febrile patients per the sepsis pathway; consider transfusion if hemoglobin drops ≥ 2 g/dL from baseline or is < 7 g/dL with symptoms.
- Multimodal and non-pharmacologic measures: warm packs, distraction, and cognitive techniques.
Inpatient and longitudinal management
- Hematology referral for disease-modifying therapy: initiate or escalate hydroxyurea for adults with ≥ 3 moderate-to-severe crises per year, interference with daily life, or prior ACS.
- Assess eligibility for newer agents (L-glutamine, voxelotor, crizanlizumab) in consultation with hematology.
- Review vaccinations and infection prophylaxis (annual influenza; pneumococcal, meningococcal, hepatitis B).
- Opioid stewardship: transition to an oral regimen before discharge and arrange an outpatient pain plan with prescription monitoring.
- Educate on hydration, avoiding temperature extremes, and presenting early for fever or chest pain.
Monitoring and disposition
- Reassess pain score and sedation level every 30–60 minutes during titration, then every 2–4 hours on the ward.
- Daily weight, intake/output, and renal function while on IV fluids and NSAIDs.
- Monitor for opioid adverse effects (respiratory depression, constipation) and NSAID toxicity (renal, GI).
- Discharge when pain is controlled on oral analgesics, the patient is afebrile, and there are no evolving complications; arrange close hematology follow-up within 1–2 weeks.
Escalate care if
- A new pulmonary infiltrate with fever or hypoxia — treat as acute chest syndrome: consider ICU, broad-spectrum antibiotics, and simple or exchange transfusion per hematology.
- Persistent severe pain despite escalating opioids — consult the pain service and consider patient-controlled analgesia (PCA).
- Altered mental status, seizure, or a focal deficit — obtain emergent neuroimaging for stroke and proceed to exchange transfusion.
Duration
NSAID course of 5–7 days; taper the opioid to oral as soon as feasible; hydroxyurea is chronic, indefinite therapy once started.
Caveats
- Avoid NSAIDs in advanced CKD or active GI bleeding.
- Use caution with high-volume IV fluids in heart failure or renal impairment.
References
- Research Reveals Avenues for Informing and Improving Sickle Cell Care. · Primary guideline“ASH and NHLBI guidelines recommend that patients experiencing vaso-occlusive crises receive opioid pain medication within 60 minutes of arrival at a hospital ED.”
- Sickle Cell Disease Guidelines: Management of Acute and Chronic Pain. · Primary guideline“Acute and chronic pain remain among the most frequent, burdensome, and challenging complications of sickle cell disease (SCD) across the lifespan.”
- Evidence-Based Management of Sickle Cell Disease. · Primary guideline“In adults with SCA who have three or more sickle cell-associated moderate to severe pain crises in a 12-month period, treat with hydroxyurea.”
- American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. (2020) · Primary guideline“For adults and children with acute pain related to SCD, the ASH guideline panel suggests a short course (5 to 7 days) of nonsteroidal anti-inflammatory drugs.”
- Sickle cell acute painful episode (CG143). · Primary guideline“IV ketoprofen (300 mg/day) then 100 mg oral ketoprofen (every 8 hours).”